
Conference Coverage
Latest News

Tagraxofusp Shows Manageable Safety Profile, Modest Activity as Monotherapy in Myelofibrosis

Adult Obesity Linked to Increased Risk of Severe Infections, Multicohort Study Finds

Improving Access, Adherence, and Outcomes Through Pharmacist-Driven CPAs

Pembrolizumab-Induced Adrenal Insufficiency: Recognizing and Managing a Diagnostic Challenge in Adjuvant NSCLC Therapy

Cetirizine and Levocetirizine Withdrawal Pruritus: What Pharmacists Need to Know About the FDA’s New Safety Warning

Shorts










Podcasts
Videos
Continuing Education
All News

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

The FDA accepts Moderna’s mRNA flu vaccine filing, targeting adults 50 years and older, with an accelerated path for seniors and a 2026 decision deadline.

Reevaluating menopause hormone therapy myths, risks, timing, and access.

FDA accepts Iberdomide new drug application for relapsed or refractory multiple myeloma; pharmacists prepare for oral anti-CD38 combos, MRD-driven care.

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

Trusted pharmacist guidance, motivational interviewing, and evidence-based resources help parents make informed pediatric immunization decisions.

FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.

Why SSRI Tapering Gets Harder at Lower Doses: The Role of Serotonin Transporter Occupancy
Serotonin transporter occupancy explains sertraline withdrawal symptoms and helps distinguish relapse.

IV push iron sucrose safety amid shortages and breakthroughs in BCMA bispecifics and menin inhibitors reshape myeloma and leukemia care.

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

The Past, Present, and Future of the Pharmacy Workforce
This century has seen a dramatic shortage of pharmacists, then a dramatic pullback, and now a selective shortage. Will artificial intelligence tip the scale? If so, in which direction(s) and which settings of care?

FDA Approves Pitolisant for Treatment of Cataplexy in Pediatric Narcolepsy
Pitolisant is now the first and only FDA-approved nonscheduled treatment for cataplexy in pediatric and adult patients with narcolepsy.

The FDA approves a once-monthly dosing schedule for amivantamab and hyaluronidase-lpuj to optimize administration and cut down infusion times.

FDA Approves Filkri, Filgrastim Biosimilar Referencing Neupogen for Cancer Treatment–Related Indications
The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatments.

Telehealth expands physical therapy and pharmacy support.

Explore the balance of ambition and self-care in cancer care, emphasizing curiosity, collaboration, and the importance of sustainable productivity.

Amivantamab with lazertinib emerges as a promising front-line therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.

Beyond the Finish Line: Why the Pharmacy of Tomorrow is a Patient Journey, Not a Prescription Fill
With user expectations changing and the need to support patients throughout their entire treatment journey, growing technology-enabled communication allows pharmacists to build stronger relationships and go beyond prescription fill.

Aspirin Reduced Development of Preeclampsia in Pregnant Patients With and Without Chronic Hypertension
Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

Investigational Therapy ALZ-801 Shows Clinical Efficacy in MCI Stage of Alzheimer Disease
ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Niels Lund, expert investigator, reveals how early type 2 diabetes care slashes greenhouse gas emissions, boosts life years, and curbs costly complications.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Experts: How Diabetes Medications May Influence Long-Term Cognitive Health
Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.




























